三鑫医疗(300453.SZ)发布上半年业绩，归母净利润1.15亿元，增长8.35%

Core Viewpoint - Sanxin Medical (300453.SZ) reported a revenue of 761 million yuan for the first half of 2025, reflecting a year-on-year growth of 10.83% [1] - The net profit attributable to shareholders was 115 million yuan, an increase of 8.35% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [1] Financial Performance - Revenue for the reporting period reached 761 million yuan, marking a 10.83% increase compared to the previous year [1] - Net profit attributable to shareholders was 115 million yuan, showing an 8.35% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 103 million yuan, which is a 9.26% increase year-on-year [1] - Basic earnings per share were reported at 0.2207 yuan [1] Business Strategy - The company has expanded its domestic and international markets by leveraging its full product chain layout of "blood dialysis equipment + consumables" [1] - Sanxin Medical emphasizes its competitive advantages in "quality + cost + service" to enhance the operational performance of its main products [1]